Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
Umbralisib is a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).